The global contract manufacturing of injectable drugs market was valued at USD 12.5 billion in 2018 and is expected to grow at a CAGR of 11.3% over the forecast period. Increasing prevalence of chronic diseases, fostering demand for biologics in coming years along with patent cliff are key factors driving the growth of the global contract manufacturing of injectable drugs market.
Healthcare systems worldwide are going through a phase of fundamental transformation. As populations age, they become more susceptible to chronic diseases such as cancer, neurological conditions and inflammation. These disorders are increasingly being treated by new therapies based on biologicals. This is just one of the reasons for the increasing importance of biopharmaceuticals, with all signs pointing to further growth in the segment; and consequently, create a larger demand for contract manufacturing organizations (CMOs) with well-rounded expertise in bio manufacturing.
Adroit Market Research report on global contract manufacturing of injectable drugs market gives a holistic view of the market from 2015 to 2025, which includes factors such as market drivers, restraints, opportunities, and challenges. The market has been studied for historic years from 2015 to 2018, with the base year of estimation as 2018 and forecast from 2019 to 2025. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market competition with Porter's five forces analysis and company positioning based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global contract manufacturing of injectable drugs market have been studied in detail.
Europe currently holds the largest share in contract manufacturing of injectable drugs market owing to the presence of significant number of contract manufacturers for injectable in the region along with growing investments by contract manufacturers on using advance manufacturing processes. Furthermore, Asia Pacific is going to record growth at a faster pace on account of developing healthcare infrastructure.
The scope of the report is segmented into type, sterilization technologies, application, and region. In the type segment, small molecule held the largest market share in 2018 and will continue to dominate throughout the forecast period. This is attributed to the increasing number of product approvals by healthcare authorities globally.
Based on the sterilization technologies, the radiation sterilization segment accounted for significant revenue share in 2018 and is expected to register the fastest growth over the forecast period. Increasing use of radiation sterilization methods, particularly for parental products is in turn anticipated to drive the growth of this segment over the forecast period. Based on application, the blood segment held the largest revenue share in 2018. Furthermore, oncology segment is expected to register the fastest growth over the forecast period.
The prominent players operating in global contract manufacturing of injectable drugs market includes Jubilant Life Sciences, Ltd., Boehringer Ingelheim, Pfizer CentreOne, Aenova Group, Baxter Biopharma Solutions, Recipharm AB, Lonza, Famar Health Care Services, Patheon Inc., Catalent Inc, Almac Group, Evonik Industries AG, Siegfried Holding AG, Consort Medical Plc, and Grifols SA.
Key segments of the global contract manufacturing of injectable drugs market
Type Overview, 2015-2025 (USD Million)
- Small Molecule
- Large Molecule
Sterilization Technologies Overview, 2015-2025 (USD Million)
- Chemical & Gas Sterilization
- Filtration Sterilization
- Radiation Sterilization
- Thermal Sterilization
Application Overview, 2015-2025 (USD Million)
Regional Overview, 2015-2025 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Central and South America
- Rest of Central and South America
- Middle East & Africa
- Rest of Middle East and Africa